NCT07145944

Brief Summary

At present, renal biopsy is the gold standard for evaluating the pathology of renal transplants, but it is invasive and has the risk of serious complications; and the sampled tissue is only a small part of the kidney, which is prone to sampling bias and lacks reliable and comprehensive detection results. Therefore, it is an urgent problem to develop a non-invasive dynamic detection method for renal insufficiency and transplanted kidney. With the continuous development and updating of technology, imaging provides a new way for non-invasive evaluation of renal allograft pathology including rejection reaction, acute renal allograft injury, viral infection, etc. MRI technology has developed the diagnosis of renal allograft rejection, fibrosis and other renal allograft dysfunction from macroscopic simple biomorphological changes to microscopic complex pathophysiological changes due to its high resolution of soft tissue and its ability to perform multi-parameter analysis. In recent years, under the background of precision medicine, artificial intelligence technologies such as radiomics and machine learning are rapidly becoming very promising auxiliary tools in the evaluation of transplanted kidney images. They can extract and learn features in images with high throughput, make greater use of information that cannot be recognized by human eyes in medical images, and realize disease diagnosis, prognosis evaluation, and curative effect prediction by establishing models. However, most of the current research is in the preliminary stage. There are few evaluation studies on kidney transplantation. It is believed that with the continuous improvement of algorithms and optimization of models, radiomics and machine learning will make great progress, which will promote the development of individualized and precise medicine for patients with renal insufficiency to a certain extent.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
500

participants targeted

Target at P75+ for all trials

Timeline
68mo left

Started Sep 2025

Longer than P75 for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress11%
Sep 2025Dec 2031

First Submitted

Initial submission to the registry

August 21, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

August 28, 2025

Completed
4 days until next milestone

Study Start

First participant enrolled

September 1, 2025

Completed
5.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2030

Expected
12 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 12, 2031

Last Updated

August 28, 2025

Status Verified

August 1, 2025

Enrollment Period

5.3 years

First QC Date

August 21, 2025

Last Update Submit

August 21, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • ESKD

    The patient reaches CKD stage 5 and the glomerular filtration rate is less than 15 ml/min

    From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months

Study Arms (1)

renal allograft patients

renal allograft patients

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

renal allograft patients

You may qualify if:

  • (1) Patients with MR examination after kidney transplantation;
  • (2) Age/gender: unlimited;
  • (3) Patients who voluntarily participate in clinical trials and sign written subject informed consent

You may not qualify if:

  • \- (1) Patients with pacemakers, unknown materials, metal implants, neurostimulators, claustrophobia, etc.
  • (2) Patients who cannot tolerate adequate breath-holding for adequate MR examination;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Rejection, Psychology

Condition Hierarchy (Ancestors)

Social BehaviorBehavior

Central Study Contacts

Zhen Professor Li, PHD,MD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

August 21, 2025

First Posted

August 28, 2025

Study Start

September 1, 2025

Primary Completion (Estimated)

December 30, 2030

Study Completion (Estimated)

December 12, 2031

Last Updated

August 28, 2025

Record last verified: 2025-08